Exact Sciences (NASDAQ:EXAS) Stock, Quote.Headers.trade-ideas

Exact Sciences

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.

News

Movers

AVGO

BNTX

CHWY

EXAS

FSLR

MSTR

ORCL

ROKU

SMMT

WOOF

These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings. 

Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?

Stock market analysts

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ARMK

DCBO

RNXT

Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

Biotech

Earnings

Large Cap

General

Exact Sciences (NASDAQ: EXAS) closed the last trading session at $59.11, gaining 3.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $79.40 indicates a 34.3% upside potential.

Wall Street Analysts Believe Exact Sciences Could Rally 34.33%: Here&#39;s is How to Trade

Exact Sciences Corporation - Common Stock

Exact Sciences Corp

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

AMGN

ILMN

MRNA

RPRX

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

Investors with a lot of money to spend have taken a bullish stance on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with EXAS, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Exact Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 33%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $117,000, and 8, calls, for a total amount of $372,081.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $85.0 for Exact Sciences during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total volume of 2,211.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Exact Sciences's big money trades within a strike price range of $55.0 to $85.0 over the last 30 days.
<h3>Exact Sciences Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726511438_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.3</td>
<td>$3.9</td>
<td>$3.9</td>
<td>$65.00</td>
<td>$117.0K</td>
<td>10</td>
<td>300</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$3.0</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$67.50</td>
<td>$59.0K</td>
<td>4.1K</td>
<td>1.1K</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$14.7</td>
<td>$14.5</td>
<td>$14.6</td>
<td>$55.00</td>
<td>$58.3K</td>
<td>1.8K</td>
<td>279</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.3</td>
<td>$2.4</td>
<td>$2.75</td>
<td>$85.00</td>
<td>$55.0K</td>
<td>131</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$11.7</td>
<td>$10.4</td>
<td>$10.9</td>
<td>$62.50</td>
<td>$52.3K</td>
<td>421</td>
<td>52</td>
</tr>
</tbody>
</table>

<h3>About Exact Sciences</h3>
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
<h3>Exact Sciences's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,695,220, the price of EXAS is up by 1.8%, reaching $66.72.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 44 days from now.</li>
</ul>
<h3>What The Experts Say On Exact Sciences</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $78.33333333333333.
<ul>
<li>An analyst from Wells Fargo downgraded its action to Overweight with a price target of $75. </li>
<li>Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Exact Sciences, targeting a price of $75. </li>
<li>Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Exact Sciences, targeting a price of $85. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Exact Sciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Exact Sciences Unusual Options Activity For September 16

WIIM

Exas Science shares are trading higher after the company announced data for its blood-based colorectal cancer screening test.

Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonoscopy. Results were presented today at the European Society for Medical Oncology (ESMO) Congress in an oral presentation titled, "Organ-specific performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort."

Exact Sciences Unveils Data on Blood-Based Colorectal Cancer Test at ESMO

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares rocketed 98.32% after the company announced it raised&nbsp;<a href="https://www.benzinga.com//node/40833208" target="_blank" rel="noreferrer noopener">$235 million&nbsp;in net proceeds</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) stock gained 31.77% in the last week after GSK halted development of the Herpes Simplex Virus Vaccine, clearing the path for other contenders like Moderna and BioNTech.</li>
<li>Applovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) stock jumped 28.38% as several analysts raised<a href="https://www.benzinga.com/quote/app/analyst-ratings" target="_blank" rel="noreferrer noopener"> the price target on the stock</a>.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) stock escalated 21.37%. The stock possibly jumped amid sympathy with Petco Health and Wellness Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) after the company <a href="https://www.benzinga.com//node/40822147" target="_blank" rel="noreferrer noopener">reported&nbsp;financial results</a>.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) shares increased 20.81%. The stock may be up amid a <a href="https://www.benzinga.com//node/40852990" target="_blank" rel="noreferrer noopener">rebound in some chip stocks</a>.</li>
<li>Arm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) shares gained 20.50% after Raymond James initiated coverage on the stock with an Outperform rating and announced <a href="https://www.benzinga.com/quote/arm/analyst-ratings" target="_blank" rel="noreferrer noopener">a $160 price target</a>.</li>
<li>MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) stock upped 18.74% after the company announced purchasing 18,300 bitcoins (CRYPTO: BTC/USD).</li>
<li>Kinross Gold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) shares increased 17.14% after the company announced it completed a Preliminary Economic <a href="https://www.benzinga.com//node/40788842" target="_blank" rel="noreferrer noopener">Assessment for the Great Bear project</a>.</li>
<li>Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) stock gained 17.10% in the last week on continued strength after a recently announced multi-year partnership with Charter to integrate linear video and streaming services to enhance flexibility and value in video bundles.</li>
<li>Vertiv Holdings, LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) stock upped 17.02%.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40869968/moderna-tyson-foods-and-adobe-are-among-top-10-large-cap-stock-losers-last-week-sep-8-sep-14-are-t">Moderna, Tyson Foods And Adobe Are Among Top 10 Large Cap Stock Losers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?</a></li>
</ul>
Image via Chewy

Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and maintains $75 price target.

Canaccord Genuity Maintains Buy on Exact Sciences, Maintains $75 Price Target

Exact Sciences shares are trading higher after Piper Sandler raised its price target on the stock from $75 to $85.

In the preceding three months, 9 analysts have released ratings for Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Exact Sciences, revealing an average target of $74.0, a high estimate of $85.00, and a low estimate of $67.00. Observing a downward trend, the current average is 12.8% lower than the prior average price target of $84.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1726164020_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Exact Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exact Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Exact Sciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Exact Sciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>Delving into Exact Sciences's Background</h2>
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
<h3>Exact Sciences: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Exact Sciences showcased positive performance, achieving a revenue growth rate of 12.41% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Exact Sciences's net margin is impressive, surpassing industry averages. With a net margin of -2.26%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Exact Sciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.5%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Exact Sciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.24%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.87, Exact Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Exact Sciences

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Needham raised the price target for Docebo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) from $45 to $50. Needham analyst Ryan MacDonald maintained a Buy rating. Docebo shares fell 0.9% to close at $41.29 on Wednesday. <a href="https://www.benzinga.com/quote/DCBO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Ascendiant Capital increased the price target for RenovoRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) from $8 to $8.25.. Ascendiant Capital analyst Edward Woo maintained a Buy rating. RenovoRx shares rose 0.1% to close at $1.05 on Wednesday. <a href="https://www.benzinga.com/quote/rnxt/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised Instil Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) price target from $25 to $40. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Instil Bio shares gained 20.6% to close at $29.65 on Wednesday. <a href="https://www.benzinga.com/quote/til/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $580 to $535. Baird analyst David Tarantino maintained an Outperform rating. Domino&#8217;s shares fell 2.1% to close at $407.97 on Wednesday. <a href="https://www.benzinga.com/quote/dpz/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised the price target for Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) from $75 to $85. Piper Sandler analyst David Westenberg maintained an Overweight rating. Exact Sciences shares gained 9.8% to close at $64.12 on Wednesday. <a href="https://www.benzinga.com/quote/exas/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities boosted Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) price target from $37 to $42. Truist Securities analyst Jasper Bibb maintained a Buy rating. Aramark shares gained 0.5% to close at $37.99 on Wednesday. <a href="https://www.benzinga.com/quote/armk/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley increased TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) price target from $96 to $103. Morgan Stanley analyst Toni Kaplan maintained an Overweight rating. TransUnion shares rose 0.2% to close at $96.44 on Wednesday. <a href="https://www.benzinga.com/quote/tru/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho cut the price target for Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) from $45 to $38. Mizuho analyst David Bellinger maintained a Neutral rating. Advance Auto Parts shares rose 0.6% to close at $38.77 on Wednesday. <a href="https://www.benzinga.com/quote/aap/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted American Tower Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) price target from $205 to $221. Mizuho analyst Vikram Malhorta maintained a Neutral rating. American Tower shares fell 1.6% to close at $238.97 on Wednesday. <a href="https://www.benzinga.com/quote/amt/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BTIG raised Alcon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) price target from $98 to $104. BTIG analyst Ryan Zimmerman maintained a Buy rating. Alcon shares rose 0.1% to close at $98.22 on Wednesday. <a href="https://www.benzinga.com/quote/dpz/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying EXAS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-1024x517.png" alt="" class="wp-image-544353" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-768x387.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100.png 1342w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well">Jim Cramer: &#8216;Not The Time To Own Oil,&#8217; When Asked About Exxon Mobil; Says IBM Is &#8216;Performing Well&#8217;</a></li>
</ul>

Piper Sandler analyst David Westenberg maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and raises the price target from $75 to $85.

Piper Sandler Maintains Overweight on Exact Sciences, Raises Price Target to $85

Deep-pocketed investors have adopted a bullish approach towards Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in EXAS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 28 extraordinary options activities for Exact Sciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 57% leaning bullish and 32% bearish. Among these notable options, 4 are puts, totaling $278,937, and 24 are calls, amounting to $1,400,044.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $75.0 for Exact Sciences over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Exact Sciences stands at 1642.89, with a total volume reaching 34,681.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Exact Sciences, situated within the strike price corridor from $55.0 to $75.0, throughout the last 30 days.
<h3>Exact Sciences Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726083056_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$6.0</td>
<td>$5.1</td>
<td>$5.3</td>
<td>$60.00</td>
<td>$179.1K</td>
<td>5.0K</td>
<td>2.8K</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$3.9</td>
<td>$3.0</td>
<td>$3.9</td>
<td>$62.50</td>
<td>$117.0K</td>
<td>1.5K</td>
<td>650</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$2.0</td>
<td>$0.5</td>
<td>$0.7</td>
<td>$55.00</td>
<td>$104.9K</td>
<td>4.3K</td>
<td>3.1K</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$6.3</td>
<td>$4.6</td>
<td>$6.3</td>
<td>$60.00</td>
<td>$99.7K</td>
<td>5.0K</td>
<td>2.4K</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$2.8</td>
<td>$1.4</td>
<td>$2.8</td>
<td>$60.00</td>
<td>$93.2K</td>
<td>5.0K</td>
<td>1.4K</td>
</tr>
</tbody>
</table>

<h3>About Exact Sciences</h3>
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Having examined the options trading patterns of Exact Sciences, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Exact Sciences Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,015,141, the price of EXAS is up by 11.94%, reaching $65.35.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 49 days from now.</li>
</ul>
<h3>What The Experts Say On Exact Sciences</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $75.0.
<ul>
<li>An analyst from Wells Fargo has revised its rating downward to Overweight, adjusting the price target to $75. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Exact Sciences with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on EXAS Options

Exact Sciences shares are trading higher after the company raised its 2024 adjusted EBITDA guidance. Also, the company announced it expects FDA approval for Cologuard Plus in H2 2024.

- Baird Global Healthcare Conference&nbsp;&nbsp;&nbsp;

Guidance

Exact Expects FDA Approval For Cologuard Plus In Second Half Of 2024, Featuring 30% Lower False-Positive Rate Compared To Original Cologuard, Improving Cancer Sensitivity And Specificity

Exact Sciences Raises Their 2024 Adjusted EBITDA Guidance After Strong Q2 Performance, Achieving Record Profitability; Expanding Margins While Reinvesting In Growth, Aiming For Over 20% EBITDA Margins By 2027

Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. &nbsp;
<ul>
<li>Baird Global Healthcare Conference, New York Fireside chat on Wednesday, September 11, 2024 at 10:15 a.m. ET</li>
</ul>
The webcasts can be accessed in the investor relations section of Exact Sciences' website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exactsciences.com&amp;esheet=54114213&amp;newsitemid=20240828766318&amp;lan=en-US&amp;anchor=www.exactsciences.com&amp;index=1&amp;md5=74b5c2dfc69085a06051488e46c59d37">www.exactsciences.com</a>.

Events

Watching Exact Sciences; Shares Spike Higher, Co Now Presenting At The Baird Global Healthcare Conference In A Fireside Chat At 10:15 a.m. ET

Exact Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exas#NASDAQ">EXAS</a>) closed the last trading session at $59.11, gaining 3.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $79.40 indicates a 34.3% upside potential.
The average comprises 20 short-term price targets ranging from a low of $61 to a high of $100, with a standard deviation of $9.54. While the lowest estimate indicates an increase of 3.2% from the current price level, the most optimistic estimate points to a 69.2% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That&#39;s because the ability and unbiasedness of analysts in setting price targets have long been questionable.
But, for EXAS, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company&#39;s ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn&#39;t gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
<h2>Here&#39;s What You May Not Know About Analysts&#39; Price Targets</h2>
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company&#39;s fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock&#39;s price movement. While that doesn&#39;t necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
<h2>Here&#39;s Why There Could be Plenty of Upside Left in EXAS</h2>
Analysts&#39; growing optimism over the company&#39;s earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That&#39;s because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The Zacks Consensus Estimate for the current year has increased 5% over the past month, as one estimate has gone higher compared to no negative revision.
Moreover, EXAS currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock&#39;s potential upside in the near term.
Therefore, while the consensus price target may not be a reliable indicator of how much EXAS could gain, the direction of price movement it implies does appear to be a good guide.
<a href="https://www.zacks.com/stock/news/2333461/wall-street-analysts-believe-exact-sciences-exas-could-rally-34-33-here-s-is-how-to-trade?cid=CS-BENZ-FT-tale_of_the_tape|consensus_price_target-2333461">To read this article on Zacks.com click here.</a>

Wall Street Analysts Believe Exact Sciences Could Rally 34.33%: Here's is How to Trade

Illumina, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) has secured the FDA&#39;s approval for its in vitro diagnostic (IVD) TruSight Oncology&nbsp;Comprehensive test and first two companion diagnostic (CDx) indications. The test analyses more than 500 genes to profile a patient&#39;s solid tumor, improving the chances of identifying an immuno-oncology or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.
The latest development marks a long-awaited milestone for the company&#39;s oncology customers and community. In Europe, a separate CE-marked version of TSO Comprehensive has been available since its launch in 2022.&nbsp;
<h2>Role of ILMN&#39;s TSO Comprehensive Test as a CDx</h2>
A CDx test can reveal whether a patient&#39;s tumor has a specific gene change or biomarker that can be targeted by a therapy, helping to determine if a patient should receive the treatment. Illumina&#39;s TSO Comprehensive is FDA-approved as a CDx to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions that may benefit from treatment with Bayer&#39;s VITRAKVI (larotrectinib). VITRAKVI is a highly selective TRK inhibitor approved for use in patients with TRK fusion cancer, in accordance with therapeutic labeling.
NTRK gene fusions are rare across most solid cancer tumor types (~0.1%&ndash;0.3%) and can be challenging to detect, given that these genes can fuse with different partners, many of which were previously unknown. TSO Comprehensive interrogates ribonucleic acid and can identify a broad range of known and novel gene fusion partners across all three NTRK gene fusions, NTRK1, NTRK2 and NTRK3.
Most CDx tests are specific to one type of cancer, however, TSO Comprehensive is approved for use across solid tumor indications for the NTRK CDx. This helps to maximize the chances of finding actionable information from each patient&#39;s biopsy.
<h2>Importance of ILMN&#39;s TSO Comprehensive in NSCLC Treatment</h2>
The test is also approved to identify adult patients with locally advanced or metastatic rearranged during transfection (RET) fusion-positive non-small-cell lung cancer (NSCLC) that may benefit from treatment with Eli Lilly&#39;s RETEVMO (selpercatinib) &mdash; a highly selective and potent RET kinase inhibitor in locally advanced or metastatic NSCLC.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6a/75694.jpg?v=224811459" />
Image Source: Zacks Investment Research
As one of the most common types of lung cancer and the leading cause of cancer-related deaths globally, NSCLC has an expansive actionable biomarker landscape. This has driven the need for broad molecular profiling to better understand the patient&#39;s disease and guide clinical management. The oncogenic activation of RET fusion-positive NSCLC by gene fusions is a primary driver in NSCLC, occurring in up to 2% of cases.
TSO Comprehensive enables broad characterization and simultaneous detection of multiple prognostic and predictive biomarkers such as RET, genomic signatures such as tumor mutational burden and emerging biomarkers within NSCLC in a single test.
<h2>Collaborations Boost Illumina&#39;s Cancer Efforts</h2>
Illumina&#39;s partnerships with industry leaders like Bayer and Lilly are crucial to advancing cancer diagnostics and expanding access to precision oncology for more patients. The company is developing a pipeline of CDx claims through partnerships with pharmaceutical companies, which will be added to TSO Comprehensive following appropriate regulatory approvals. These CDx claims will help unlock groundbreaking targeted therapies and immunotherapies to benefit cancer patients.
TSO Comprehensive will start shipping to customers this year. Comprehensive genomic profiling assays with CDx claims for solid tumors, like TSO Comprehensive, are reimbursable under Centers for Medicare &amp; Medicaid Service national coverage determination.
<h2>Industry Prospects Favors Illumina</h2>
Per a Grand View Research report, the global oncology CDx market was valued at $4.78 billion in 2023 and projected to grow at a compound annual growth rate (CAGR) of 8.7% by 2030.
The market is growing due to the increasing prevalence of cancer, the growing adoption of CDx and a rising emphasis on personalized medicine. The need for early cancer detection tests, which can help improve disease management &amp; reduce mortality, is expected to propel the overall market growth.
<h2>Illumina&#39;s Recent Developments</h2>
Earlier this month, the company expanded its oncology menu for the NovaSeq X Series customers with the high-throughput version of TruSight Oncology 500 and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2. These assays enable labs to confidently expand oncology testing research of tissue and liquid biopsy samples, with new transformative sequencing economics, faster sequencing run times and broader batch sizes on the NovaSeq X Series for the first time.
<h2>ILMN Stock Price, Consensus and EPS Surprise</h2>
In the past year, ILMN shares have lost 17.2% compared with the industry&#39;s decline of 2.3%.
In the past 30 days, Illumina&#39;s 2024 estimated earnings have surged nearly 94% to $3.16 per share. The stock has beat estimates in each of the trailing four quarters, the average surprise being 463.5%.
<h2>ILMN&#39;s Zacks Rank and Other Top MedTech Stocks</h2>
Illumina currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the broader medical space are Exact Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exas#NASDAQ">EXAS</a>), Boston Scientific and SiBone (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sibn#NASDAQ">SIBN</a>), each carrying a Zacks Rank #2 (Buy) at present.
Exact Sciences&#39; shares have lost 25.2% in the past year. Estimates for the company&#39;s loss per share have improved from $1.09 to 95 cents in 2024 and from 26 cents to 6 cents in 2025 in the past 30 days. EXAS&#39; earnings beat estimates in three of the trailing four quarters and matched in one, delivering an average surprise of 56.2%. In the last reported quarter, it posted an earnings surprise of 75.7%.
Estimates for Boston Scientific&#39;s 2024 earnings per share have moved to $2.40 from $2.36 in the past 30 days. Shares of the company have gained 48.1% in the past year compared with the industry&#39;s growth of 13.9%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%. In the last reported quarter, it delivered an earnings surprise of 6.9%.
Estimates for SiBone&#39;s 2024 loss per share have narrowed to 89 cents from 95 cents in the past 30 days. Shares of the company have lost 23% in the past year against the industry&#39;s 11.4% growth. SIBN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
<a href="https://www.zacks.com/stock/news/2328511/ilmn-s-tso-comprehensive-ivd-test-secures-fda-approval-as-cdx?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2328511">To read this article on Zacks.com click here.</a>

Earnings Beats

Small Cap

SIBN

ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx

Wells Fargo analyst Brandon Couillard initiates coverage on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight rating and announces Price Target of $75.

Initiation

Wells Fargo Initiates Coverage On Exact Sciences with Overweight Rating, Announces Price Target of $75

Insulet Corp.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/podd#NASDAQ">PODD</a>) groundbreaking Omnipod 5 Automated Insulin Delivery (&quot;AID&quot;) system (Omnipod 5) received the FDA&#39;s approval for use by type 2 diabetes patients (ages 18 years and above). The news comes after the company submitted 510(k) for an expanded indication of Omnipod 5 to the FDA, in June 2024, based on the favorable clinical outcomes of the SECURE-T2D pivotal trial.
With this development, Omnipod 5 is the first and only AID system indicated for both type 1 and type 2 diabetes.
<h2>Insulet&#39;s Robust Opportunity in the Type 2 Space</h2>
Diabetes is a chronic and life-threatening disease for which there is no known cure. The more common variant, type 2 diabetes, is characterized by the body&#39;s inability to either properly utilize or produce enough insulin. More than 30 million people are living with type 2 diabetes in the United States, with approximately 6 million people requiring insulin. Of these, roughly 2.5 million are using multiple daily injections (&quot;MDI&quot;) &mdash; a form of insulin therapy that involves injecting fast-acting insulin before meals (bolus) to lower blood glucose levels to a healthy range.
Although medical therapies have advanced in the past 20 years, the percentage of adults with type 2 diabetes achieving recommended HbA1c (a common measure of blood glucose levels) targets&nbsp;has not seen any significant change. Only a quarter of individuals with type 2 diabetes on insulin are achieving an HbA1c of 7% or less and half of this population has an HbA1c greater than 8%.&nbsp;Despite guideline recommendations for insulin treatment in advanced disease, insulin therapy is often delayed or not appropriately intensified.
<h2>The SECURE-T2D Trial Boosts Approval of PODD&#39;s Omnipod 5</h2>
This is the largest study ever completed for the use of AID in type 2 diabetes, featuring highly diverse study participants who are representative of the general population in the United States. Insulet recently presented data showing that Omnipod 5 significantly improves health outcomes while making life easier for people with type 2 diabetes.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/2f/75532.jpg?v=2091424716" />
Image Source: Zacks Investment Research
The trial demonstrated that compared with prior insulin therapy methods in adults with type 2 diabetes, using Omnipod 5 resulted in considerable reductions in HbA1c &mdash; 0.8% overall and 2.1% in those with prior HbA1c 9% or higher. Time in hyperglycemia and total daily insulin dose were also reduced. In addition, there was a 20% improvement in time in range, increasing 4.8 hours per day, without increasing time in hypoglycemia. The study also demonstrated a clinically meaningful improvement in diabetes distress.
<h2>Insulet&#39;s Omnipod 5 Simplifies Type 2 Diabetes Management</h2>
The latest announcement from the company represents a significant milestone for the treatment of type 2 diabetes, providing an easy-to-use, patient-centric technology. The tubeless pod therapy, Omnipod 5, has set a new standard in diabetes management, allowing individuals to achieve better health outcomes while giving them greater confidence and freedom in their daily lives. Insulet&#39;s president and CEO expressed excitement about the opportunity to make a lasting impact on the insulin-requiring type 2 diabetes community.
The Omnipod 5 System leads to improved results by eliminating the need for MDI and automatically adjusting insulin delivery every 5 minutes, using its advanced SmartAdjust technology. As the top-rated and most prescribed pump in the United States, Omnipod 5 is waterproof, discreet and wearable. This is the first tubeless AID system that communicates with a continuous glucose monitor, proactively correcting for highs and protecting against lows, day and night. The system is easy to prescribe through the pharmacy and widely covered by many insurance plans, including Medicare Part D.
<h2>Insulet&#39;s Prospects in the Type 2 Diabetes Industry</h2>
Per a Precedence Research report, the global market for type 2 diabetes was valued at $32 billion in 2022 and expected to witness a CAGR of 8.2% by 2032.
The introduction of new, more effective and safer therapeutic compounds is paving the way for the development of new treatments. Additionally, the rising obesity epidemic in many regions of the world is boosting the industry&#39;s profitability. &nbsp;
Recent Developments of Insulet
Insulet unveiled its new state-of-the-art manufacturing facility in Malaysia this month, which strategically positions the company to cater to the huge demand for Omnipod. The 400,000-square-foot facility strengthens the company&#39;s global operational capabilities and supply chain resiliency and currently runs with a local workforce that has been upskilled and trained.
<h2>PODD&#39;s Price Performance</h2>
In the past year, Insulet shares have lost 0.3% against the industry&#39;s rise of 14%.
<h2>Zacks Rank and Key MedTech Stocks</h2>
Insulet currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Exact Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exas#NASDAQ">EXAS</a>), Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>), and SiBone (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sibn#NASDAQ">SIBN</a>). Each of these carries a Zacks Rank #2 (Buy) at present.
Exact Sciences&#39; shares have fallen 25.3% in the past year. Estimates for the company&#39;s loss per share have improved from $1.09 to 95 cents in 2024 and from 26 cents to 6 cents in 2025 in the past 30 days. EXAS&#39; earnings beat estimates in three of the trailing four quarters and matched in one, delivering an average surprise of 56.2%. In the last reported quarter, it posted an earnings surprise of 75.7%.
Estimates for Boston Scientific&#39;s 2024 earnings per share have moved to $2.40 from $2.36 in the past 30 days. Shares of the company have gained 47.8% in the past year compared with the industry&#39;s growth of 13.7%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%. In the last reported quarter, it delivered an earnings surprise of 6.9%.
Estimates for SiBone&#39;s 2024 loss per share have narrowed to 89 cents from 95 cents in the past 30 days. Shares of the company have lost 20.6% in the past year against the industry&#39;s 12.3% growth. SIBN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
<a href="https://www.zacks.com/stock/news/2327736/insulet-s-omnipod-5-wins-fda-approval-for-type-2-diabetes?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2327736">To read this article on Zacks.com click here.</a>

PODD

Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes

Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), a leading provider of cancer screening and diagnostic tests, today announced that the first patient has joined its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence (RWE) study at Baylor Scott &amp; White, the primary study site and largest not-for-profit health system in Texas. The multi-site study will enroll up to 25,000 patients, evaluating the clinical performance, patient and provider experience, and psychological impact of MCED testing over a five-year period. Endeavor Health, a Chicago-area health system serving more than 1.4 million patients, will start enrolling patients this fall. The U.S. Food and Drug Administration (FDA) recently authorized an investigational device exemption (IDE) for the Exact Sciences MCED test, allowing its use in the Falcon Registry. This study will provide valuable insight to further inform the development and commercialization of the company's future MCED test and support discussions with regulatory agencies, payers, and guideline bodies.

Government

Regulations

Exact Sciences Launches Multi-Cancer Early Detection Study with 25K Patients, Supported by FDA Authorization

Fidelity Select Health Care Portfolio Q2 2024 Review

Exact Sciences spikes ahead of data for blood-based cancer test

In a report released today, Vijay Kumar from Evercore ISI maintained a Buy rating on Exact Sciences (EXAS – Research Report), with a price target o...

Buy Rating for Exact Sciences: Anticipated Growth from Upcoming Catalysts and Competitive Pricing

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Seres Therapeutics (MCRB – Research Report), BioMarin Pharmaceuti...

Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)

Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target of $75....

Buy Rating Affirmed for Exact Sciences Amid Anticipation of New CRC Screening Data

Exact Sciences gains 6% following data on blood-based colorectal cancer test

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark Massaro from BTI...

Buy Rating Affirmed for Exact Sciences on Robust CRC Test Results and Strategic Pipeline Advancements

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target of $75.00. ...

Buy Rating for Exact Sciences: Promising CRC Screening Test Outperforms with High Accuracy and Market Potential

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00. Tycho Peterson...

Buy Rating Affirmed for Exact Sciences Following Promising CRC Screening Test Data

28 Top rated U.S. growth stocks month-to-date in anticipation of Fed cuts

AFRM

ALNY

AQST

ARIS

BMRN

BMYMP

CHEF

CVEO

EPRT

GKOS

IBKR

INSP

INTA

KVUE

LWAY

MCRB

NECB

NONOF

PLOW

POWL

PRCT

REGN

SKYW

SPYG

TILE

TMUS

TOST

TTWO

VEEV

VICI

VOOG

Screenshot 2024-08-30 at 6.27.59 PM

MYNZ

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Screenshot 2024-06-20 at 6.58.26 PM

Mainz Biomed&#39;s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

Screenshot 2024-06-04 at 5.31.42 PM

Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate

Press Releases

Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

Exact Sciences Announces Second-Quarter 2024 Results

TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology

New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion

Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study

Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)

Exact Sciences to Participate in September Investor Conferences

Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Exact Sciences

Exact Sciences (EXAS) Forecast

Exact Sciences (NASDAQ:EXAS) Stock, Quote.Headers.trade-ideas